Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boost.
• Moderna stock is at critical resistance. Why are MRNA shares at highs?
Moderna and Merck & Co Inc. (NYSE:MRK) announced positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene, an individualized mRNA-based neoantigen therapy, in patients with completely resected stage IIB-IV melanoma. The combination of intismeran and Merck’s Keytruda delivered statistically significant improvements in both recurrence-free survival and distant metastasis-free survival versus Keytruda alone.
The result is particularly significant because it represents the first positive Phase 3 readout for an individualized mRNA cancer therapy.
For ETF investors, however, the bigger question is whether this can revive the broader precision-medicine trade.
Read Also: Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions
Moderna’s Cancer Win Changes the mRNA Narrative
The mRNA investment story has long centered on vaccines, but Merck and Moderna’s latest result points to a bigger opportunity: personalized cancer treatments tailored to each patient’s tumor mutations.
The companies have worked on the therapy since 2016, with Merck exercising its option to co-develop and commercialize it in 2022. The partners split development costs and profits equally.
For Moderna, the therapy offers a path beyond COVID products; for Merck, it could strengthen its oncology franchise. Keytruda generated $31.7 billion in 2025 sales, making a successful personalized cancer vaccine a potentially important long-term growth driver.
Which ETFs Could Benefit?
The most direct thematic exposure comes from the iShares Genomics Immunology and Healthcare ETF (NYSE:IDNA). The fund currently holds Moderna and Merck at roughly 8% of assets cumulatively. IDNA holds 50 companies spanning genomics, immunology and bioengineering, making it a relatively targeted way to capture the precision-medicine theme rather than simply the broader pharmaceutical sector. The fund surged 13% on Wednesday.
The ARK Genomic Revolution ETF (BATS:ARKG) offers a more aggressive version of the trade. Its mandate focuses on companies involved in genomics, molecular medicine, gene therapy and related innovation. ARKG gained 64% so far in 2026, highlighting how strongly the genomics theme has already been performing. ARK was up 10% at market close on Wednesday.
For investors wanting broader biotech exposure, the SPDR S&P Biotech ETF (NYSE:XBI) and iShares Biotechnology ETF (NASDAQ:IBB) provide different approaches. XBI uses a modified equal-weight structure across 155 holdings, while IBB held 247 companies. XBI was trading 5.90% higher, and IBB was 6.58% higher at market close on Wednesday.
The Bigger ETF Trade
The Moderna-Merck result does not mean personalized cancer vaccines are suddenly a commercial certainty. Detailed clinical data, regulatory review, manufacturing economics and results across additional tumor types still matter.
But it does change the conversation.
If mRNA can successfully move from infectious-disease vaccines into individualized oncology, the opportunity extends well beyond Moderna. Sequencing, genomics, diagnostics, immunology and drug discovery could all become part of the same investment ecosystem.
For ETF investors, that makes IDNA and ARKG the more targeted ways to play the precision-medicine narrative, while XBI and IBB offer broader exposure to a potential biotech revival.
The COVID-era mRNA trade may be over. The mRNA-for-cancer trade could be just beginning.
Read Also: Moderna's Cancer Vaccine Win Is Merck's Story Too
Photo: Shutterstock
.png?w=600)
